2 recruiting, 1 completed, 1 not yet recruiting. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 2, Completed 1, Not yet recruiting 1 |
Follow Platinum Doublet Chemotherapy: new trials by email Literature Review of Platinum Doublet Chemotherapy trials Research Report on Platinum Doublet Chemotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Cancer Circulating Tumor Deoxyribonucleic acid (ctDNA) Assay, Pembrolizumab, Platinum Doublet Chemotherapy - Non Small Cell Lung Cancer | Phase 2 | Recruiting | University of Miami | 30 | 2025-06-11 | 2026-07-22 |
| Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC) Golidocitinib, Sintilimab, platinum doublet chemotherapy - Non-Small-Cell Lung Cancer | Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 69 | 2024-01-01 | 2024-01-10 |
| Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab Durvalumab, Olaparib tablet, Single-agent chemotherapy - Non-small-cell Lung Cancer Patients | Phase 2 | Recruiting | Fondazione Ricerca Traslazionale | 176 | 2022-05-02 | 2025-12-01 |
| Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer Nivolumab, Ipilimumab, Platinum Doublet Chemotherapy - Non-Small-Cell Lung Cancer | Phase 2 | Completed | Bristol-Myers Squibb | 324 | 2016-02-15 | 2023-04-05 |
Carcinoma, Non-Small-Cell Lung (3)
Bristol-Myers Squibb (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Fondazione Ricerca Traslazionale (1) · University of Miami (1)
United States (2) · Canada (1) · China (1) · Italy (1)
Federico Cappuzzo, MD (1) · Jie Wang, MD,PhD (1) · Richa Dawar, MD (1)